SCHEMBL25156702

SCHEMBL25156702

COc1cc(C(C)O)c2ccccc2c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CDC25B P30305 4/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2A6 P11509 1/20 0.46
▸ UGT2B7 P16662 1/20 0.42
▸ CASP3 P42574 1/20 0.41
▸ SENP7 Q9BQF6 1/20 0.41
▸ NQO1 P15559 1/20 0.40
▸ NQO2 P16083 1/20 0.40
▸ CYP2D6 P10635 2/20 0.39
▸ GPR84 Q9NQS5 1/20 0.39
▸ AKR1B1 P15121 1/20 0.38
▸ KDM2B Q8NHM5 2/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ BCHE P06276 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30344621 1.00 CDC25B (0.47) CDC25BCYP1A2CYP2A6UGT2B7CASP3
SCHEMBL20314895 0.86 CYP1A2 (0.53) CDC25BCYP1A2CYP2A6CASP3SENP7
SCHEMBL3929101 0.81 CYP2D6 (0.50) CYP1A2CYP2A6CYP2D6ADRA2AADRA1A
SCHEMBL3929104 0.81 CYP2D6 (0.50) CYP1A2CYP2A6CYP2D6ADRA2AADRA1A
SCHEMBL31581619 0.77 CDC25B (0.49) CDC25BCYP1A2GPR84
SCHEMBL21120749 0.77 CYP1A2 (0.53) CYP1A2CYP2A6UGT2B7NQO2KDM2B
SCHEMBL31524012 0.76 CDC25B (0.48) CDC25BCYP1A2CASP3SENP7GPR84
SCHEMBL16033860 0.76 TRPM4 (0.48) CYP1A2CYP2A6UGT2B7NQO2CYP2D6
SCHEMBL911036 0.74 NQO2 (0.61) CDC25BCYP1A2CYP2A6CASP3SENP7
SCHEMBL29428606 0.74 NQO2 (0.61) CDC25BCYP1A2CYP2A6CASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023064493-A1 COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES Clear Creek Bio, Inc. (US) 2023-04-20 — — WO disclosed
Send feedback